Literature DB >> 6244358

Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate.

B Blazar, M Patarroyo, E Klein, G Klein.   

Abstract

Superinfection of latently Epstein-Barr virus (EBV)-carrying Raji cells with the P3HR-1 substrain EBV, known to induce the entry of a substantial fraction of cells into an abortively lytic cycle, increased the susceptibility of the cells to natural killer (NK) effect of human blood lymphocytes. Reciprocal cold-target competition tests with known NK-cell sensitive and -resistant lymphoid cell ines showed that the increased susceptibility is a result of the appearance of an NK-sensitive target, rather than to a general increase in membrane fragility. Lymphocytes of EBV-seropositive and -negative donors were equally effective killers against P3HR-1 virus-superinfected targets. EBV-induced NK sensitivity increased with time. It was a result of some event associated with the intracellular viral cycle, and not to the adherence of viral particles to the cell surface. Induction of EBV-carrying P3HR-1 cells to entry into the viral cycle with n-butyrate also increased their NK sensitivity. A transforming, noncytopathic prototype strain of EBV, B95-8, failed to increase the susceptibility of theRaji cells to NK-lysis, although it had some effect on the Daudi line. Because NK cells can kill virus-producing cells at an early stage of the cycle, before the virus particles are assembled, they may restrict, in vivo, the spread of the virus from latently infected cells.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6244358      PMCID: PMC2185807          DOI: 10.1084/jem.151.3.614

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

2.  Synthesis of Epstein-Barr virus after activation of the viral genome in a "virus-negative" human lymphoblastoid cell (Raji) made resistant to 5-bromodeoxyuridine (thymidine kinase-virus antigen-immunofluorescence-herpesvirus fingerprints).

Authors:  B Hampar; J G Derge; L M Martos; J L Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

3.  Occurrence of Epstein-Barr virus genomes in human lymphoblastoid cell lines.

Authors:  H zur Hansen; V Diehl; H Wolf; H Schulte-Holthausen; U Schneider
Journal:  Nat New Biol       Date:  1972-06-07

4.  Detection of Epstein-Barr viral genome in nonproductive cells.

Authors:  M Nonoyama; J S Pagano
Journal:  Nat New Biol       Date:  1971-09-22

5.  Presence of EB virus nucleic acid homology in a "virus-free" line of Burkitt tumour cells.

Authors:  H Zur Hausen; H Schulte-Holthausen
Journal:  Nature       Date:  1970-07-18       Impact factor: 49.962

6.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

Authors:  M A Epstein; B G Achong; Y M Barr; B Zajac; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1966-10       Impact factor: 13.506

7.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

8.  Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.

Authors:  P Lindahl; P Leary; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

9.  Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis.

Authors:  V Diehl; G Henle; W Henle; G Kohn
Journal:  J Virol       Date:  1968-07       Impact factor: 5.103

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

View more
  19 in total

1.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.

Authors:  M Yanagisawa; M Kato; K Ikeno; T Kobayashi; Y Miyagawa; A Komiyama; T Akabane
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

3.  The mother lode of liver transplantation, with particular reference to our new journal.

Authors:  T E Starzl
Journal:  Liver Transpl Surg       Date:  1998-01

4.  Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.

Authors:  M A Nalesnik; A S Rao; A Zeevi; J J Fung; S Pham; H Furukawa; A Gritsch; G Klein; T E Starzl
Journal:  Transplant Proc       Date:  1997-05       Impact factor: 1.066

Review 5.  Natural killer cells in resistance to virus-infected cells.

Authors:  B Rager-Zisman; B R Bloom
Journal:  Springer Semin Immunopathol       Date:  1982

6.  Epstein-Barr (EB) virus antibodies in rheumatoid arthritis.

Authors:  P B Ferrell; E M Tan
Journal:  Springer Semin Immunopathol       Date:  1981

7.  Lysis of uninfected and virus-infected cells in vivo: a rejection mechanism in addition to that mediated by natural killer cells.

Authors:  C A Biron; S Habu; K Okumura; R M Welsh
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

Review 8.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

9.  Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.

Authors:  E Vilmer; G M Lenoir; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

10.  Cytotoxic effector cells from infectious mononucleosis patients in the acute phase do not specifically kill Epstein-Barr virus genome-carrying lymphoid cell lines.

Authors:  P C Patel; G Dorval; J Menezes
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.